Want to see SE:SPEC full AI Analyst Report?

SpectraCure AB (SPEC) Price & Analysis

1 Followers

SPEC Stock Chart & Stats

kr0.18

kr0.10(5.82%)

At close: Mar 06 4:00 PM EST

kr0.18

kr0.10(5.82%)

Day’s Range― - ―

52-Week Rangekr0.02 - kr0.19

Previous CloseN/A

Volume60.95K

Average Volume (3M)10.04M

Market Cap

kr24.68M

Enterprise Valuekr39.03M

Total Cash (Recent Filing)kr7.63M

Total Debt (Recent Filing)kr8.91M

Price to Earnings (P/E)―

Beta-0.12

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding1,426,541,500

10 Day Avg. Volume4,447,486

30 Day Avg. Volume10,036,141

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-1.46

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Balance-Sheet LeverageLow debt relative to equity limits direct balance-sheet pressure from borrowing and preserves some financial flexibility. This gives SpectraCure more room to pursue clinical development and commercialization without the immediate constraints associated with heavy leverage.

Targeted Therapy PlatformA minimally invasive platform combining treatment delivery with real-time monitoring addresses a clinically focused need in tumor ablation. The integrated approach may support differentiated adoption if clinical development and regulatory progress validate its use in prostate cancer.

Equipment And Recurring Consumables ModelThe planned model combines upfront system placements with procedure-related consumables, creating the potential for a recurring revenue component after clinical adoption. That structure could improve revenue durability compared with relying solely on one-time equipment sales.

Bears Say

No Current RevenueThe absence of reported revenue alongside substantial operating and net losses shows that the business has not yet demonstrated commercial traction. Until sales begin and scale, SpectraCure remains exposed to a prolonged development period without operating leverage.

Persistent Cash BurnSustained negative operating and free cash flow means current operations do not fund the company’s needs. Continued development and commercialization therefore depend on existing reserves or external funding, creating an ongoing constraint on financial independence.

Shrinking Equity BaseThe shrinking equity base indicates that persistent losses are consuming shareholder capital, despite modest leverage. Deeply negative returns also show that invested capital is not yet generating value, increasing the risk that future funding will be needed to sustain operations.

SPEC FAQ

What was SpectraCure AB’s price range in the past 12 months?

SpectraCure AB lowest stock price was kr0.02 and its highest was kr0.19 in the past 12 months.

What is SpectraCure AB’s market cap?

SpectraCure AB’s market cap is kr24.68M.

When is SpectraCure AB’s upcoming earnings report date?

SpectraCure AB’s upcoming earnings report date is Nov 13, 2026 which is in 35 days.

How were SpectraCure AB’s earnings last quarter?

SpectraCure AB released its earnings results on Aug 21, 2026. The company reported -kr0.008 earnings per share for the quarter.

Is SpectraCure AB overvalued?

According to Wall Street analysts SpectraCure AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SpectraCure AB pay dividends?

SpectraCure AB does not currently pay dividends.

What is SpectraCure AB’s EPS estimate?

SpectraCure AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SpectraCure AB have?

SpectraCure AB has 1,426,541,500 shares outstanding.

What happened to SpectraCure AB’s price movement after its last earnings report?

SpectraCure AB reported an EPS of -kr0.008 in its last earnings report. Following the earnings report the stock price went up 5.405%.

Which hedge fund is a major shareholder of SpectraCure AB?

Currently, no hedge funds are holding shares in SE:SPEC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SpectraCure AB

SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.